Literature DB >> 11778799

Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability.

C E Brightling1, W Monterio, R H Green, D Parker, M D Morgan, A J Wardlaw, D Pavord.   

Abstract

The forced expiratory volume in 1 sec (FEV1) is the most established outcome measure in chronic obstructive pulmonary disease (COPD). However, changes in FEV1 in response to treatment are small in relation to the repeatability of the measurement and there is increasing interest in other measures including markers of lower airway inflammation in induced sputum, assessment of symptoms and health status using visual analogue scores, and questionnaires. Little is known about the repeatability of these measures or the safety of sputum induction in COPD. We have assessed the safety of sputum induction in 61 subjects with moderate and severe COPD who participated in a placebo-controlled cross-over study The within-subject repeatability of sputum markers of airway inflammation, health status using the chronic respiratory disease questionnaire (CRQ) and symptom visual analogue scores (VAS) were estimated from the data obtained from before and after 2 weeks of treatment with placebo. Sputum induction was performed on 122 occasions and was successful resulting in a cytospin adequate to assess a differential cell count in 95% of inductions. The group mean (SEM) FEV1 was 1.09 (0.05)[41.6 (2.9)% predicted] and the mean (SEM) fall in FEV1 after sputum induction was 120 ml (6) and % fall 10.9% (0.55%). Seven inductions were stopped due to a fall in FEV1 >20% and at a further 13 visits the full sputum induction protocol was not completed due to development of symptoms. The reproducibility of measurements, calculated by the intra-class correlation coefficient, was relatively high for all indices measured (0.4-0.95) with the exception ofthe proportion of lymphocytes (0.15) and epithelial cells (0.3). The ICC for symptom scores and the CRQ domains ranged between 0.87 and 0.96. In conclusion, sputum induction is safe and the cell and fluid phase mediators repeatable in the investigation of airway inflammation in patients with COPD. VAS symptom scores and the CRQ are reproducible outcome measures in COPD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11778799     DOI: 10.1053/rmed.2001.1195

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  30 in total

1.  Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  Jeong H Yun; Andrew Lamb; Robert Chase; Dave Singh; Margaret M Parker; Aabida Saferali; Jørgen Vestbo; Ruth Tal-Singer; Peter J Castaldi; Edwin K Silverman; Craig P Hersh
Journal:  J Allergy Clin Immunol       Date:  2018-04-28       Impact factor: 10.793

2.  Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.

Authors:  Mike Berry; Angela Morgan; Dominick E Shaw; Deborah Parker; Ruth Green; Christopher Brightling; Peter Bradding; Andrew J Wardlaw; Ian D Pavord
Journal:  Thorax       Date:  2007-03-13       Impact factor: 9.139

3.  Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study.

Authors:  Dave Singh; Lisa Edwards; Ruth Tal-Singer; Stephen Rennard
Journal:  Respir Res       Date:  2010-06-15

4.  An Open-Label, Multi-Institutional, Randomized Study to Evaluate the Additive Effect of a Leukotriene Receptor Antagonist on Cough Score in Patients with Cough-Variant Asthma Being Treated with Inhaled Corticosteroids.

Authors:  Nanako Miwa; Tatsuya Nagano; Hisashi Ohnishi; Teruaki Nishiuma; Kazuhiro Takenaka; Tomohiko Shirotani; Takeo Nakajima; Ryota Dokuni; Yoshitaka Kawa; Kazuyuki Kobayashi; Yasuhiro Funada; Yoshikazu Kotani; Yoshihiro Nishimura
Journal:  Kobe J Med Sci       Date:  2018-12-04

5.  Local and systemic oxidative stress status in chronic obstructive pulmonary disease patients.

Authors:  Mian Zeng; Yue Li; Yujie Jiang; Guifang Lu; Xiaomei Huang; Kaipan Guan
Journal:  Can Respir J       Date:  2013 Jan-Feb       Impact factor: 2.409

6.  Comparison of airway immunopathology of eosinophilic bronchitis and asthma.

Authors:  C E Brightling; F A Symon; S S Birring; P Bradding; A J Wardlaw; I D Pavord
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

7.  Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids.

Authors:  R H Green; C E Brightling; G Woltmann; D Parker; A J Wardlaw; I D Pavord
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

8.  Airway microbiome is associated with respiratory functions and responses to ambient particulate matter exposure.

Authors:  Liping Wang; Haoxiang Cheng; Dongbin Wang; Bo Zhao; Jushan Zhang; Long Cheng; Pengfei Yao; Antonio Di Narzo; Yuan Shen; Jing Yu; Yuanyuan Li; Shunqing Xu; Jia Chen; Lihong Fan; Jianwei Lu; Jingkun Jiang; Yang Zhou; Changhui Wang; Zhongyang Zhang; Ke Hao
Journal:  Ecotoxicol Environ Saf       Date:  2018-10-18       Impact factor: 6.291

9.  Glutathione and nitrite levels in induced sputum at COPD patients and healthy smokers.

Authors:  Teyfik Turgut; Nevin Ilhan; Figen Deveci; Nusret Akpolat; Ersin Şükrü Erden; M Hamdi Muz
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

10.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.

Authors:  Mona Bafadhel; Susan McKenna; Sarah Terry; Vijay Mistry; Mitesh Pancholi; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.